UK's Creo Medical FY25 revenue rises 50%

Creo Medical

20/01/2026 07:12

Overview

UK medical device firm's FY25 revenue grew 50%

Company reduced underlying operating costs by 20% in FY25

Underlying operating loss reduced by over 40% in FY25

Outlook

Creo expects FY26 revenue growth and improved operational efficiency

Company aims for self-sustaining cashflows and increased shareholder value

Creo's products strategically positioned in growing markets for potential returns

Result Drivers

CLINICAL ADOPTION - Increased clinical adoption and demand for Creo's core products drove revenue growth

PRODUCT LAUNCHES - Launch of SpydrBlade™ Flex and MicroBlate™ Flex contributed to revenue growth

COST CONTROL - 20% reduction in operating costs due to actions taken in FY24 and continued cost control

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Adjusted EBIT
-GBP 13.30 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Creo Medical Group PLC is GBp40.00, about 226.5% above its January 19 closing price of GBp12.25

Press Release: ID:nRST5118Pa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)